NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Pancreatic enzyme for HIV-associated steatorrhea: a controlled clinical trial.

Steuerwald MH, Scott MK, Garcia-Shelton YL, Keiserman M, Cello JP, Koch J; International Conference on AIDS.

Int Conf AIDS. 1996 Jul 7-12; 11: 298 (abstract no. Th.B.4271).

San Francisco General Hospital, San Francisco, CA. Fax: (415) 641-0745. E-mail: hannes@itsa.ucsf.edu.

Objective: To determine the impact of pancreatic enzyme supplementation on steatorrhea in patients with chronic HIV-associated diarrhea. Methods: Nineteen patients with chronic diarrhea (duration greater than 3 months) and no identifiable pathogen on stool culture, examination for ova and parasites or on endoscopic duodenal biopsies agreed to participate in the study. Study Design: Open-label time series. Setting: General Clinical Research Center. Duration: ten days. Intervention: The study participants received a diet containing at least 100 grams of fat per day for the duration of the study. After measurements at baseline, the participants were given lipase (Pancrease, McNeil Pharmaceutical) at a dose of 4000 units per meal and 2000 units per snacks. Measurements: Number of bowel movements, total stool weight, dry stool weight and fecal fat during 72 hours off (days 2-4) and on (days 7-9) study medication respectively. Results: The mean age of the 19 men was 39.8 plus or minus 7.1 years, the median CD4+ count 192 cells/mm3. 6 patients had had an AIDS defining illness, 10 had a CD4+ count of less than 200/mm3. Measurements for total stool weight and bowel movements were obtained in all patients, however, complete stool analysis could be performed in only 10 patients due to significant laboratory inconsistencies. Fecal fat excretion correlated well with dry stool weight (R2=0.8). (table: see text) Conclusions: 1. High dose pancreatic enzyme supplementation enhanced fat digestion, expressed as a significant decrease in the ratio of fecal fat/solid stool weight. 2. High dose pancreatic enzyme supplementation did not result in a clinical benefit in this short-term study, expressed as no decrease in number of daily bowel movements, total and solid stool weight or fecal fat excretion.

Publication Types:
  • Meeting Abstracts
Keywords:
  • AIDS Vaccines
  • Acquired Immunodeficiency Syndrome
  • Body Weight
  • CD4 Lymphocyte Count
  • Diarrhea
  • Fats
  • Feces
  • HIV Infections
  • HIV Seropositivity
  • Humans
  • Lipase
  • Male
  • Nutritional Status
  • Pancreas
  • Pancrelipase
  • Steatorrhea
Other ID:
  • 96924662
UI: 102220561

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov